In this Aug. 14, 2018 file photo, a doctor looks at PET brain scans in Phoenix.
Matt York / AP Photo
In this Aug. 14, 2018 file photo, a doctor looks at PET brain scans in Phoenix.
Matt York / AP Photo
(Washington) — The Food and Drug Administration approved aducanumab to treat patients with Alzheimer’s disease Monday morning. It is the first new drug approved by the agency for Alzheimer’s disease since 2003.
The drug is the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer’s disease.
The drug has proved highly effective at reducing the plaques, called beta amyloid, that build up in the brains of people with Alzheimer’s.
But two large studies offered conflicting evidence about whether the treatment slows declines in memory and thinking. A panel of expert advisers to the FDA recommended in November that the agency not approve the drug.
As a condition of approval, the FDA is requiring Biogen, the drug’s maker, to conduct another clinical study to confirm that the reduction of amyloid plaques results in clinical improvement for patients. If the subsequent study doesn’t show a clinical improvement, the agency could move to withdraw the approval.
The medicine will be marketed under the trade name Aduhelm.
Patients will receive the drug in monthly infusions. They will also need regular brain scans to detect a rare side effect: bleeding or swelling in the brain.
Biogen and Eisai, the companies marketing the drug, have yet to announce how much it will cost.
The Alzheimer’s Association, which has been pushing for approval, applauded the news.
“This is the first drug that slows Alzheimer’s disease. And, this is the beginning of a completely new future for Alzheimer’s treatments,” it said in a statement. “This is a new type of Alzheimer’s treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs.”
We spotlight and uplift the creators around us, featuring amazing artists, musicians, authors, chefs, dancers, designers, photographers, and more.
The days of journalism’s one-way street of simply producing stories for the public have long been over. Now, it’s time to find better ways to interact with you and ensure we meet your high standards of what a credible media organization should be.